Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kurt Miller

Showing results (261-270 of 290) with videos related to

Pageof 29
Sort By:
BJU International|August 16, 2014
Enzalutamide in European and North American men participating in the AFFIRM trialAxel S Merseburger, Howard I Scher, Joaquim Bellmunt, et al.
Deutsche Medizinische Wochenschrift (1946)|May 17, 2019
[Medicine and Economy: Measures for a Science Based, Patient-Centred and Resource Conscious Care. The Association of Scientific Medical Societies' (AWMF) Strategy Paper]Monika Nothacker, Reinhard Busse, Peter Elsner, et al.
International Journal of Biological Sciences|November 10, 2012
Identification of metastamirs as metastasis-associated microRNAs in clear cell renal cell carcinomasZofia Wotschofsky, Julia Liep, Hellmuth-Alexander Meyer, et al.
Plos One|January 9, 2016
Dynamics of Urinary Calprotectin after Renal IschaemiaJan Ebbing, Felix S Seibert, Nikolaos Pagonas, et al.
European Urology|September 15, 2014
Achievements and perspectives in prostate cancer phase 3 trials from genitourinary research groups in Europe: introducing the Prostate Cancer Consortium in EuropeKarim Fizazi, Per-Anders Abrahamsson, Goran Ahlgren, et al.
Eclinicalmedicine|May 30, 2023
Clinical outcomes and treatment patterns in REASSURE: planned interim analysis of a real-world observational study of radium-223 in metastatic castration-resistant prostate cancerCelestia S Higano, Daniel J George, Neal D Shore, et al.
European Urology Oncology|June 13, 2019
Automated Bone Scan Index as an Imaging Biomarker to Predict Overall Survival in the Zometa European Study/SPCG11Mariana Reza, Manfred Wirth, Teuvo Tammela, et al.
The Lancet. Oncology|April 19, 2015
Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trialYohann Loriot, Kurt Miller, Cora N Sternberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 13, 2009
Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95Thomas Wiegel, Dirk Bottke, Ursula Steiner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2005
Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, phase III trial (AUO-AB 05/95)Jan Lehmann, Margitta Retz, Christina Wiemers, et al.
Pageof 29

Showing results (261-270 of 290) with videos related to

Sort By:
Pageof 29
BJU International|August 16, 2014
Enzalutamide in European and North American men participating in the AFFIRM trialAxel S Merseburger, Howard I Scher, Joaquim Bellmunt, et al.
Deutsche Medizinische Wochenschrift (1946)|May 17, 2019
[Medicine and Economy: Measures for a Science Based, Patient-Centred and Resource Conscious Care. The Association of Scientific Medical Societies' (AWMF) Strategy Paper]Monika Nothacker, Reinhard Busse, Peter Elsner, et al.
International Journal of Biological Sciences|November 10, 2012
Identification of metastamirs as metastasis-associated microRNAs in clear cell renal cell carcinomasZofia Wotschofsky, Julia Liep, Hellmuth-Alexander Meyer, et al.
Plos One|January 9, 2016
Dynamics of Urinary Calprotectin after Renal IschaemiaJan Ebbing, Felix S Seibert, Nikolaos Pagonas, et al.
European Urology|September 15, 2014
Achievements and perspectives in prostate cancer phase 3 trials from genitourinary research groups in Europe: introducing the Prostate Cancer Consortium in EuropeKarim Fizazi, Per-Anders Abrahamsson, Goran Ahlgren, et al.
Eclinicalmedicine|May 30, 2023
Clinical outcomes and treatment patterns in REASSURE: planned interim analysis of a real-world observational study of radium-223 in metastatic castration-resistant prostate cancerCelestia S Higano, Daniel J George, Neal D Shore, et al.
European Urology Oncology|June 13, 2019
Automated Bone Scan Index as an Imaging Biomarker to Predict Overall Survival in the Zometa European Study/SPCG11Mariana Reza, Manfred Wirth, Teuvo Tammela, et al.
The Lancet. Oncology|April 19, 2015
Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trialYohann Loriot, Kurt Miller, Cora N Sternberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 13, 2009
Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95Thomas Wiegel, Dirk Bottke, Ursula Steiner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2005
Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, phase III trial (AUO-AB 05/95)Jan Lehmann, Margitta Retz, Christina Wiemers, et al.
Pageof 29